8-K: Mallinckrodt and Endo to Merge, Creating Pharmaceutical Giant

Mallinckrodt and Endo have announced a definitive agreement to combine in a stock and cash transaction, aiming to create a global, scaled, diversified pharmaceuticals leader.

Summary

• Endo and Mallinckrodt have agreed to merge, forming a larger pharmaceutical company.
• The transaction involves a combination of stock and cash.
• Endo shareholders will receive $80 million in cash and own 49.9% of the combined company.
• Mallinckrodt shareholders will own 50.1% of the combined company.
• The implied pro forma enterprise value is $6.7 billion.
• The combined company expects to generate at least $150 million in annual operating synergies by year 3, with approximately $75 million in year 1.
• Pro forma 2025 revenue is projected to be $3.6 billion, and adjusted EBITDA is expected to be $1.2 billion.
• The combined company intends to separate the combined sterile injectables and generics business at a later date.
• Net leverage is expected to be approximately 2.3x at close.
• Endo reported fourth-quarter 2024 revenues of $467 million, a 6% decrease compared to the previous year.
• Net loss for Endo in the fourth quarter was $349 million.
• Endo's adjusted EBITDA for the fourth quarter was $164 million.
• Endo's 2025 revenue guidance is $1,775 to $1,860 million, and adjusted EBITDA guidance is $620 to $650 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to the merger announcement and expected synergies. However, there are also some negative aspects, such as the decrease in Endo's fourth-quarter revenues and adjusted net income. Overall, the sentiment is moderately positive.

Positives

• The merger is expected to create a larger and more diversified entity with enhanced financial flexibility.
• The combined company will have a strong balance sheet and compelling synergy opportunities.
• The merger is expected to generate at least $150 million of annual pre-tax run-rate operating synergies by Year 3.
• The combined company will possess a branded business with the scale, cash flow and balance sheet strength to invest in both internal and external growth opportunities.
• Endo's XIAFLEX achieved record revenues of $516 million in 2024, up 9% versus 2023.
• Endo successfully launched ADRENALIN ready-to-use premixed bags.

Negatives

• Endo's fourth-quarter revenues decreased by 6% to $467 million.
• Endo's fourth-quarter adjusted net income decreased to $70 million from $151 million in the prior year.
• Endo's net cash provided by operating activities in the fourth quarter decreased to $30 million from $115 million in the prior year.
• Generic Pharmaceuticals segment revenues in fourth-quarter 2024 were $111 million, compared to $139 million in fourth-quarter 2023.

Risks

• The merger is subject to shareholder and regulatory approvals.
• The expected synergies may not be fully realized or may take longer to achieve.
• The integration of the two companies could face unanticipated difficulties.
• The separation of the combined sterile injectables and generics business may not occur as planned.
• The combined company will face competition and regulatory challenges.
• The companies' ability to obtain the approval of their shareholders and stockholders, respectively, required to consummate the proposed business combination transaction.
• Uncertainties related to a future separation of the combined generics pharmaceuticals businesses of Mallinckrodt and Endo and Endos sterile injectables business.

Future Outlook

Endo provides 2025 revenue guidance of $1,775 to $1,860 million and adjusted EBITDA guidance of $620 to $650 million. The combined company is expected to generate pro forma 2025 revenue of $3.6 billion and pro forma 2025 Adjusted EBITDA of $1.2 billion.

Management Comments

• We ended the year strong, with XIAFLEX annual revenues exceeding $500 million for the first time and the successful launch of ADRENALIN ready-to-use premixed bags, said Scott Hirsch, Interim Chief Executive Officer.
• This exciting combination will create a larger and more diversified entity with the scale and resources needed to unlock the full potential of both companies, said Siggi Olafsson, President and Chief Executive Officer of Mallinckrodt.
• We believe this combination with Mallinckrodt, along with the subsequent separation of the combined sterile injectables and generics business, presents a unique opportunity to deliver significant shareholder value, said Scott Hirsch, Interim CEO of Endo.

Industry Context

The pharmaceutical industry is constantly evolving, with companies seeking to expand their portfolios and achieve greater scale through mergers and acquisitions. This merger reflects a trend towards consolidation in the industry, with companies aiming to enhance their market position and financial performance.

Comparison to Industry Standards

• Comparing Endo and Mallinckrodt to other diversified pharmaceutical companies like Teva Pharmaceuticals or Viatris, the combined entity aims to achieve similar economies of scale and product diversification.
• The projected synergies of $150 million are within the typical range for mergers of this size in the pharmaceutical sector.
• The net leverage of 2.3x expected at close is a reasonable level compared to industry peers.

Management Changes

Stakeholder Impact

• Shareholders of both companies will be impacted by the merger, with Endo shareholders receiving cash and a stake in the combined company.
• Employees of both companies may experience changes due to the integration and potential separation of businesses.
• Customers will have access to a broader range of pharmaceutical products.
• The combined company will have enhanced financial flexibility to invest in innovation and pursue growth opportunities.

Next Steps

• Shareholder approval from both Mallinckrodt and Endo.
• Regulatory approvals.
• Closing of the transaction, expected in the second half of 2025.
• Operational combination of generics businesses and Endo's sterile injectables business.
• Potential separation of the combined sterile injectables and generics business at a later date.
• Announcement of the combined company's U.S. headquarters and corporate name.

Key Dates